claim: cytodyn to begin enrollment for leronlimab phase 2 trial to treat covid-19
evidence_1: cytodyn files ind and protocol for phase 2 clinical trial for treatment of coronavirus patients with leronlimab (pro 140) [new release].", "cytodyn files a clinical trial protocol with the fda to treat severely ill covid-19 patients with leronlimab where the primary endpoint is mortality rate at two weeks [news release].", "cytodyn has also filed for the initiation of a phase ii/iii trial for the treatment of severely ill patients with covid-19.", "we will aggressively pursue treatment for covid-19 patients, and to explore leronlimabs role in helping to alleviate the impending burden of supply chain and institutional capacity issues, said nader pourhassan, phd, president, and chief executive officer, cytodyn, in a statement.3 < < view more resources regarding covid-19 references 1.", 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  "cytodyn is, therefore, conducting a phase 1b/2 human clinical trial in metastatic triple-negative breast cancer and was granted fast track designation in may 2019.")